Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study
Status:
Completed
Trial end date:
2016-11-30
Target enrollment:
Participant gender:
Summary
Critical Limb Ischemia (CLI) is defined as limb pain that occurs at rest, or impending limb
loss that is caused by severe compromise of blood flow to the affected extremity. CLI is a
major cause of death and disability (secondary to myocardial infarction, stroke and
amputation). The mortality in patients with CLI approaches 13-25% and 50% at one and five
years respectively. High on-treatment platelet reactivity (HPR) in patients treated with
aspirin and clopidogrel is associated with increased risk of recurrent cardiovascular events
after percutaneous coronary interventions and coronary syndromes. Preliminary studies suggest
that the prevalence of HPR in patients with critical limb ischemia treated with aspirin and
clopidogrel is as high a 78.5%. In patients with coronary artery disease ticagrelor overcomes
non-responsiveness to clopidogrel. However, the antiplatelet effect of ticagrelor in patients
with critical limb ischemia is unknown.